April 2018 Market Review

Following is a summary of the markets and our funds’ performance for the month of April 2018, provided by our Chief Investment Strategist David A. Klassen.

21% of Abbvie Shareholders Favor Report on How Drug Pricing Risks are Integrated Into Exec Incentive Programs

At today’s annual shareholder meeting for Abbvie a first-time shareholder proposal questioning the links between executive compensation packages and drug price increases received a solid show of support from investors, signaling to the board of directors that this issue is key to investor confidence about the long-term sustainability of the company.